PANGAEA ONCOLOGY, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.77 EUR | -4.84% |
|
-4.84% | -3.80% |
| May. 08 | Pangaea Oncology, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 27.02 | 35.38 | 50 | 54.18 | 53.36 | - | - |
| Enterprise Value (EV) 1 | 32.36 | 35.38 | 45.24 | 54.18 | 58.86 | 60.16 | 60.26 |
| P/E ratio | -16.7 x | - | - | - | -35.4 x | -88.5 x | - |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.59 x | 7.69 x | 11.4 x | 6.77 x | 3.87 x | 3.61 x | 3.4 x |
| EV / Revenue | 7.89 x | 7.69 x | 10.4 x | 6.77 x | 4.26 x | 4.06 x | 3.84 x |
| EV / EBITDA | 42.7 x | - | -35.6 x | -36.2 x | -53.5 x | -201 x | - |
| EV / FCF | -16.3 x | - | -12.2 x | - | -29.4 x | -85.9 x | -603 x |
| FCF Yield | -6.14% | - | -8.17% | - | -3.4% | -1.16% | -0.17% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 16,887 | 22,533 | 30,490 | 29,446 | 30,145 | - | - |
| Reference price 2 | 1.600 | 1.570 | 1.640 | 1.840 | 1.770 | 1.770 | 1.770 |
| Announcement Date | 4/30/21 | 4/29/22 | 4/28/23 | 5/8/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.1 | 4.603 | 4.368 | 7.998 | 13.8 | 14.8 | 15.7 |
| EBITDA 1 | 0.757 | - | -1.27 | -1.495 | -1.1 | -0.3 | - |
| EBIT 1 | -1.664 | - | -2.559 | -2.801 | -1.2 | -0.4 | - |
| Operating Margin | -40.59% | - | -58.59% | -35.02% | -8.7% | -2.7% | - |
| Earnings before Tax (EBT) 1 | -1.907 | - | -2.839 | -3.507 | -1.5 | -0.7 | - |
| Net income 1 | -1.794 | -0.6419 | -2.724 | -4.656 | -1.5 | -0.7 | -0.1 |
| Net margin | -43.76% | -13.95% | -62.36% | -58.22% | -10.87% | -4.73% | -0.64% |
| EPS 2 | -0.0958 | - | - | - | -0.0500 | -0.0200 | - |
| Free Cash Flow 1 | -1.986 | - | -3.696 | - | -2 | -0.7 | -0.1 |
| FCF margin | -48.44% | - | -84.6% | - | -14.49% | -4.73% | -0.64% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/30/21 | 4/29/22 | 4/28/23 | 5/8/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 5.34 | - | - | - | 5.5 | 6.8 | 6.9 |
| Net Cash position 1 | - | - | 4.76 | - | - | - | - |
| Leverage (Debt/EBITDA) | 7.057 x | - | - | - | -5 x | -22.67 x | - |
| Free Cash Flow 1 | -1.99 | - | -3.7 | - | -2 | -0.7 | -0.1 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 0.07 | - | 0.02 | - | 0.1 | 0.1 | 0.2 |
| Capex / Sales | 1.73% | - | 0.46% | - | 0.72% | 0.68% | 1.27% |
| Announcement Date | 4/30/21 | 4/29/22 | 4/28/23 | 5/8/24 | - | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.80% | 60.6M | |
| +49.41% | 57.87B | |
| +41.65% | 40.25B | |
| -6.72% | 39.94B | |
| -5.96% | 28.54B | |
| +12.99% | 26.4B | |
| -19.82% | 19.33B | |
| +32.35% | 12.4B | |
| -0.08% | 12.23B | |
| +25.18% | 12.2B |
- Stock Market
- Equities
- PANG Stock
- Financials Pangaea Oncology, S.A.
